Disc Medicine SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

SCHEDULE 13D/AOct. 26, 2026, 5:52 p.m. ETView on SEC.gov
8-KOct. 22, 2026, 5:11 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Results of operations and financial condition · Other events · Financial statements and exhibits
AI summary, unreviewedDisc Medicine Prices Upsized $450 Million Common Stock Offering at $75.00 per Share, Reports $682.8 Million Preliminary Cash at September 30, 2026
4Oct. 21, 2026, 5:33 p.m. ETView on SEC.gov
424B5Oct. 21, 2026, 5:21 p.m. ETView on SEC.gov
424B5Oct. 19, 2026, 5:42 p.m. ETView on SEC.gov
8-KOct. 19, 2026, 7:08 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedDisc Medicine Reports Positive Phase 3 APOLLO Topline Results for Bitopertin in EPP, Meeting All Primary and Secondary Endpoints
4Sept. 16, 2026, 6:44 p.m. ETView on SEC.gov
4Sept. 15, 2026, 4:30 p.m. ETView on SEC.gov
8-KSept. 10, 2026, 8:48 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
4Sept. 9, 2026, 4:23 p.m. ETView on SEC.gov
4Sept. 3, 2026, 5:43 p.m. ETView on SEC.gov
4Aug. 26, 2026, 8:10 p.m. ETView on SEC.gov
4Aug. 18, 2026, 6:56 p.m. ETView on SEC.gov
4Aug. 14, 2026, 7:14 p.m. ETView on SEC.gov
4Aug. 7, 2026, 5:32 p.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 6, 2026, 10:20 a.m. ETView on SEC.gov
10-QJuly 30, 2026, 8:34 a.m. ETView on SEC.gov
8-KJuly 30, 2026, 8:32 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits